Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I/IIa Study to Evaluate the Safety, Tolerability, Whole-body Distribution, and Preliminary Diagnostic Performance of a Novel 68Ga-labelled Minigastrin Analogue in Patients With Advanced Neuroendocrine Tumours

NCT06155994 is registered in ClinicalTrials.gov with Medical University Innsbruck as lead sponsor.

NCT NCT06155994
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06155994 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I/IIa Study to Evaluate the Safety, Tolerability, Whole-body Distribution, and Preliminary Diagnostic Performance of a Novel 68Ga-labelled Minigastrin Analogue in Patients With Advanced Neuroendocrine Tumours
Lead sponsor
Medical University Innsbruck
Phase
Phase 1/2
Overall status
Completed
Start date
January 20, 2021
Completion date
June 30, 2023
Enrollment
12 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

neuroendocrine tumors